50.50
-0.85(-1.66%)
Currency In HKD
Address
Innov Tower (Capitaland Building)
Shanghai, 200233
China
Phone
86 21 3339 5800
Website
Sector
Healthcare
Industry
Biotechnology
Employees
3515
First IPO Date
September 25, 2019
| Name | Title | Pay | Year Born |
| Dr. Jun Zhu | Chief Executive Officer & Executive Director | 9.77M | 1979 |
| Dr. Shi-Kau Liu | Co-founder & Head of Strategy Advisory Committee | 6.74M | 1964 |
| Mr. Yingbo Mao | Vice President & Chief Financial Officer | 0 | 1979 |
| Ms. Miaojie Chen | Vice President of Legal & Compliance | 0 | N/A |
| Dr. Wei-Dong Jiang | Co-Founder & Co-Head of Innovative Advisory Committee | 0 | 1963 |
| Dr. Jijun Yuan | Chief Scientific Officer | 0 | 1978 |
| Ms. Junhua Li | Senior Vice President & Chief Human Resources Officer | 0 | 1977 |
| Ms. Huang Wei | President | 0 | 1969 |
| Ms. Yan Wang | Deputy GM of Public Relations & Joint Company Secretary | 0 | 1988 |
| Mr. Wallis Zeng | Vice President of Sales & Oncology Business Unit | 0 | N/A |
Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and solid tumors; HLX04-O, a bevacizumab injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20 for the treatment of solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12 for gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14 to treat osteoporosis. In addition, it develops HLX26 for the treatment of solid tumor and lymphoma; HLX13 to treat melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71 to treat COVID-19. Shanghai Henlius Biotech, Inc. operates in Mainland China, Europe, rest of Asia Pacific, and internationally. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.